|
Market Closed -
Nasdaq
02:30:00 03/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 961.26 USD | +3.60% |
|
+19.41% | +24.54% |
| Market Cap | 9.31TCr 8.31TCr 7.63TCr 6.94TCr 13TCr 8,81500Cr 13TCr 91TCr 37TCr 4,65300Cr 35TCr 34TCr 14,69600Cr | P/E 2026 * |
16.2x | P/E 2027 * | 15.5x |
|---|---|---|---|---|---|
| Enterprise Value | 8.59TCr 7.67TCr 7.04TCr 6.41TCr 12TCr 8,13600Cr 12TCr 84TCr 34TCr 4,29400Cr 32TCr 32TCr 13,56400Cr | EV / Sales 2026 * |
4.88x | EV / Sales 2027 * | 4.02x |
| Free-Float |
71.06% | Yield 2026 * |
0.39% | Yield 2027 * | 0.45% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| REGN | Delayed | |
CBOE
| REGN | Real-time | |
|
Tradegate
| RGO | Real-time | |
|
Mexican S.E.
| REGN * | End-of-day quote | |
|
Boerse Muenchen
| RGO | Real-time | |
|
London S.E.
| 0R2M | Delayed | |
|
Xetra
| RGO | End-of-day quote | |
|
Deutsche Boerse AG
| RGO | Delayed | |
|
Börse Stuttgart
| RGO | Delayed | |
|
Borsa Italiana
| 1REGN | End-of-day quote | |
|
Wiener Boerse
| REGN | End-of-day quote | |
|
Lima
| REGNUS | End-of-day quote |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +3.60% | ||
| 1 week | +19.41% | ||
| Current month | +3.60% | ||
| 1 month | +30.82% | ||
| 3 months | +26.05% | ||
| 6 months | +37.04% | ||
| Current year | +24.54% |
| 1 week | 802.2 |  | 974 |
| 1 month | 722.02 | | 974 |
| Current year | 591.52 | | 974 |
| 1 year | 591.52 | | 974 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
George Sing
BRD | Director/Board Member | 76 | 08/01/1988 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/10/26 | Sell | Chief Technology Officer | -4,147 | 0.0041% | ||
| 03/09/26 | Sell | Executive/Senior Manager | -1,131 | 0.0011% | ||
| 02/09/26 | Exercice | Director | 1,200 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.60% | +19.41% | +47.48% | +21.48% | 9.31TCr | |
| -0.46% | +10.80% | +63.52% | +154.48% | 1,26300Cr | |
| -0.97% | +2.56% | +43.25% | +81.96% | 66TCr | |
| -2.05% | +1.12% | +32.47% | +102.74% | 52TCr | |
| -1.54% | +1.61% | +53.42% | +67.10% | 39TCr | |
| -0.78% | +2.13% | +72.55% | +44.25% | 37TCr | |
| -1.69% | +2.75% | +32.49% | +54.35% | 31TCr | |
| -0.72% | +8.08% | +11.15% | +34.09% | 29TCr | |
| -0.12% | +5.96% | +55.97% | +78.44% | 25TCr | |
| -0.21% | +9.16% | +42.19% | +112.41% | 21TCr | |
| Average | -0.18% | +6.84% | +45.45% | +75.13% | 43.55TCr | |
| Weighted average by Cap. | -0.37% | +6.78% | +49.11% | +95.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.76TCr 1.57TCr 1.44TCr 1.31TCr 2.46TCr 1,66700Cr 2.51TCr 17TCr 6.94TCr 88TCr 6.61TCr 6.47TCr 2,77800Cr | 2TCr 1.79TCr 1.64TCr 1.49TCr 2.8TCr 1,89600Cr 2.85TCr 20TCr 7.9TCr 1,00100Cr 7.52TCr 7.36TCr 3,16100Cr |
| Net income | 642.63Cr 573.74Cr 526.49Cr 478.92Cr 897.92Cr 61TCr 915.81Cr 6.29TCr 2.53TCr 32TCr 2.41TCr 2.36TCr 1,01400Cr | 655.96Cr 585.64Cr 537.41Cr 488.86Cr 916.55Cr 62TCr 934.81Cr 6.42TCr 2.59TCr 33TCr 2.46TCr 2.41TCr 1,03500Cr |
| Net Debt | -716.8Cr -639.96Cr -587.25Cr -534.2Cr -1TCr -68TCr -1.02TCr -7.01TCr -2.83TCr -36TCr -2.69TCr -2.63TCr -1,13100Cr | -1.25TCr -1.12TCr -1.03TCr -932.86Cr -1.75TCr -1,18500Cr -1.78TCr -12TCr -4.94TCr -63TCr -4.7TCr -4.6TCr -1,97600Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | $961.26 | +3.60% | 16,56,689 |
| 30/26/30 | $927.89 | +13.33% | 28,70,752 |
| 29/26/29 | $818.77 | +0.68% | 7,89,303 |
| 28/26/28 | $813.27 | -0.35% | 5,36,498 |
| 27/26/27 | $816.10 | +1.04% | 7,26,151 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
